Lilly adds to pain pipeline with Asahi Kasei licensing deal

US drugmaker Eli Lilly – still waiting for an FDA decision on one non-opioid pain drug – has just added another to its pipeline via a licensing agreement with Japan’s Asahi Kasei worth up t

Satsuma pulped as acute migraine drug flunks phase 3 trial

Shares in California biotech Satsuma Pharma have lost three quarters of their value after lead drug STS01 failed to show any improvement over placebo in an acute migraine study.

FDA starts review of Pfizer, Lilly’s non-opioid painkiller

Exclusive Speaker Interview with Stephen Hunt, Professor, UC...

Exclusive Speaker Interview with Stephen Hunt

Durect's post-op painkiller splits FDA advisory panel

As the US opioid addiction crisis continues, it seems the FDA is less than convinced about the new painkilling drugs that the pharma industry is developing.

Nektar pulls pain drug after bruising FDA panel meeting